Literature DB >> 15736437

Over-expression of RNA helicases in cancer.

Mohamed Abdelhaleem1.   

Abstract

RNA helicases constitute a large group of essential enzymes involved in all aspects of RNA metabolism. With few exceptions, human RNA helicases of DDX and DHX gene families have not been well characterized. However, several of them have been shown to be dysregulated in cancer, including over-expression in various types of tumors. Although the exact contribution of RNA helicases to carcinogenesis has not been determined, their over-expression in cancer render them potential targets for novel anti-cancer agents. In this review, RNA helicases whose expression is up-regulated in cancer are highlighted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15736437

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

Review 1.  The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

Authors:  Mandy Juarez; Alejandro Schcolnik-Cabrera; Alfonso Dueñas-Gonzalez
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

2.  The DEAD-box RNA helicase DDX41 is a novel repressor of p21WAF1/CIP1 mRNA translation.

Authors:  Dominik Peters; Claudia Radine; Alina Reese; Wilfried Budach; Dennis Sohn; Reiner U Jänicke
Journal:  J Biol Chem       Date:  2017-03-27       Impact factor: 5.157

3.  Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

Authors:  Atul Kondaskar; Shilpi Kondaskar; Raj Kumar; James C Fishbein; Nidal Muvarak; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Guus M Bol; Farhad Vesuna; Venu Raman; Ramachandra S Hosmane
Journal:  ACS Med Chem Lett       Date:  2010-12-31       Impact factor: 4.345

4.  DHX32 expression is an indicator of poor breast cancer prognosis.

Authors:  Meng Wang; Guojun Zhang; Yajie Wang; Ruimin Ma; Limin Zhang; Hong Lv; Fang Fang; Xixiong Kang
Journal:  Oncol Lett       Date:  2016-12-14       Impact factor: 2.967

5.  Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.

Authors:  Claudia Cava; Gloria Bertoli; Marilena Ripamonti; Giancarlo Mauri; Italo Zoppis; Pasquale Anthony Della Rosa; Maria Carla Gilardi; Isabella Castiglioni
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

6.  Overexpression of DHX32 contributes to the growth and metastasis of colorectal cancer.

Authors:  Huayue Lin; Wenjuan Liu; Zanxi Fang; Xianming Liang; Juan Li; Yongying Bai; Lingqing Lin; Hanyu You; Yihua Pei; Fen Wang; Zhong-Ying Zhang
Journal:  Sci Rep       Date:  2015-03-18       Impact factor: 4.379

7.  Discovering the miR-26a-5p Targetome in Prostate Cancer Cells.

Authors:  Milena Rizzo; Gabriele Berti; Francesco Russo; Sofia Fazio; Monica Evangelista; Romina D'Aurizio; Marco Pellegrini; Giuseppe Rainaldi
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

8.  DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA.

Authors:  Huayue Lin; Zanxi Fang; Yuanhui Su; Peihua Li; Jingkun Wang; Hongfeng Liao; Qing Hu; Chunlei Ye; Yizhen Fang; Qing Luo; Zhiyuan Lin; Chao Pan; Fen Wang; Zhong-Ying Zhang
Journal:  EBioMedicine       Date:  2017-03-09       Impact factor: 8.143

9.  RNA helicase DHX15 acts as a tumour suppressor in glioma.

Authors:  Shingo Ito; Hideto Koso; Kazuhiro Sakamoto; Sumiko Watanabe
Journal:  Br J Cancer       Date:  2017-08-22       Impact factor: 7.640

10.  Differential tissue-specific protein markers of vaginal carcinoma.

Authors:  K Hellman; A A Alaiya; S Becker; M Lomnytska; K Schedvins; W Steinberg; A-C Hellström; S Andersson; U Hellman; G Auer
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.